JP2007508301A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508301A5
JP2007508301A5 JP2006533949A JP2006533949A JP2007508301A5 JP 2007508301 A5 JP2007508301 A5 JP 2007508301A5 JP 2006533949 A JP2006533949 A JP 2006533949A JP 2006533949 A JP2006533949 A JP 2006533949A JP 2007508301 A5 JP2007508301 A5 JP 2007508301A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
tetrahydro
benzyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533949A
Other languages
English (en)
Japanese (ja)
Other versions
JP4773969B2 (ja
JP2007508301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030907 external-priority patent/WO2005037796A1/en
Publication of JP2007508301A publication Critical patent/JP2007508301A/ja
Publication of JP2007508301A5 publication Critical patent/JP2007508301A5/ja
Application granted granted Critical
Publication of JP4773969B2 publication Critical patent/JP4773969B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533949A 2003-10-08 2004-10-07 脂質代謝異常の治療ための化合物及び方法 Expired - Fee Related JP4773969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50973603P 2003-10-08 2003-10-08
US60/509,736 2003-10-08
PCT/US2004/030907 WO2005037796A1 (en) 2003-10-08 2004-10-07 Compounds and methods for treating dyslipidemia

Publications (3)

Publication Number Publication Date
JP2007508301A JP2007508301A (ja) 2007-04-05
JP2007508301A5 true JP2007508301A5 (enExample) 2011-05-19
JP4773969B2 JP4773969B2 (ja) 2011-09-14

Family

ID=34465112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533949A Expired - Fee Related JP4773969B2 (ja) 2003-10-08 2004-10-07 脂質代謝異常の治療ための化合物及び方法

Country Status (25)

Country Link
US (1) US7749992B2 (enExample)
EP (2) EP2098512A1 (enExample)
JP (1) JP4773969B2 (enExample)
KR (1) KR20060085675A (enExample)
CN (1) CN1863778A (enExample)
AT (1) ATE442358T1 (enExample)
AU (1) AU2004282101A1 (enExample)
BR (1) BRPI0414186A (enExample)
CA (1) CA2537942A1 (enExample)
CY (1) CY1110537T1 (enExample)
DE (1) DE602004023100D1 (enExample)
DK (1) DK1670768T3 (enExample)
EA (1) EA200600737A1 (enExample)
EC (1) ECSP066484A (enExample)
ES (1) ES2332051T3 (enExample)
HR (1) HRP20090581T1 (enExample)
IL (1) IL173819A0 (enExample)
MA (1) MA28268A1 (enExample)
MX (1) MXPA06003927A (enExample)
NO (1) NO20062074L (enExample)
PL (1) PL1670768T3 (enExample)
PT (1) PT1670768E (enExample)
SI (1) SI1670768T1 (enExample)
WO (1) WO2005037796A1 (enExample)
ZA (1) ZA200602888B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470705B2 (en) * 2004-03-26 2008-12-30 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
US7652023B2 (en) * 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
CN103833636B (zh) * 2014-03-31 2015-09-02 武汉武药制药有限公司 一种莫扎伐普坦中间体的合成方法
CN108137508B (zh) * 2015-07-31 2021-08-27 艾尼纳制药公司 5-ht2c受体激动剂和组合物及使用方法
CN110291383B (zh) * 2017-02-23 2021-12-28 株式会社Ihi Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法
CN113195475A (zh) 2018-10-24 2021-07-30 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
MX2022012881A (es) 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法
CN117088814A (zh) * 2023-02-16 2023-11-21 烟台大学 一种三氟甲硫化氮杂-8/9元环化合物的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
TW270927B (enExample) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) * 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
WO1995034540A1 (en) * 1994-06-15 1995-12-21 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
JPH09214746A (ja) 1996-02-02 1997-08-15 Ricoh Co Ltd 画像出力システム及び画像形成装置
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Fo−5637a物質及びb物質並びにそれらの製造法
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6664522B2 (en) * 2000-03-30 2003-12-16 Homer L. Spencer Method and apparatus for sealing multiple casings for oil and gas wells
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
YU84303A (sh) * 2001-04-30 2006-05-25 Pfizer Products Inc. Postupak dobijanja cetp inhibitora
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
ES2358898T3 (es) 2002-07-01 2011-05-16 Cytec Surface Specialties, S.A. Precursores de polímeros diluibles en agua, su preparación y su uso.
NZ532494A (en) * 2002-08-30 2006-03-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US20060100239A1 (en) 2003-03-04 2006-05-11 Izuru Nagasaki Method for producing optically active amines
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005033082A2 (en) 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
US7470705B2 (en) * 2004-03-26 2008-12-30 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法

Similar Documents

Publication Publication Date Title
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
ES2445536T3 (es) Derivados de la pirazina y su uso en el tratamiento de trastornos neurológicos
AU2013296627C1 (en) Deuterated ibrutinib
CA3119656A1 (en) Macrocyclic compounds and their use in the treatment of disease
JP2024522292A (ja) ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
CA3164134A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
CA3190610A1 (en) Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
AU2019310508B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
JP2011522843A (ja) 新規なカリウムチャンネルブロッカー及びその使用
JP5822840B2 (ja) 眼疾患処置薬
JP6042331B2 (ja) プロテアソーム活性を向上させる三環系化合物
CA3087262A1 (en) Benzamide compounds
AU2017253937A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
EP4406616A2 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
BRPI0708331A2 (pt) compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4
JP2007508301A5 (enExample)
CN101247807A (zh) 噻唑化合物及使用方法
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
CA3256658A1 (en) BICYCLE-DERIVED PARP INHIBITOR AND ITS USE
EP3344632A1 (en) Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
JP2005527518A (ja) 新規なカルコン(chalcone)誘導体とその使用
CA3039070A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ
JP2016527228A (ja) 新規抗マラリア薬